quarkpharma.com
801 and Diabetes
Fremont, CA (April 28, 2005) -- Quark Biotech, Inc. announced today findings from a study that suggest that the hypoxia inducible gene RTP801 may serve an important role in the pathogenesis of early diabetic retinal disease. The study reveals that the knockout of RTP801 ameliorates diabetes-induced retinal vascular permeability (RVP) and electroretinogram (ERG) abnormalities